$1.04
+0.07 (+7.08%)
Open$0.97
Previous Close$0.97
Day High$1.04
Day Low$0.95
52W High$2.18
52W Low$0.86
Volume—
Avg Volume784.2K
Market Cap78.85M
P/E Ratio—
EPS$-1.78
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+4,414.4% upside
Current
$1.04
$1.04
Target
$46.95
$46.95
$33.28
$46.95 avg
$64.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.89M | 42.94M | 46.10M |
| Net Income | 949.8K | 770.7K | 699.4K |
| Profit Margin | 2.0% | 1.8% | 1.5% |
| EBITDA | 1.44M | 1.43M | 1.37M |
| Free Cash Flow | 717.1K | 500.4K | 604.2K |
| Rev Growth | -0.9% | +8.9% | +4.5% |
| Debt/Equity | 0.33 | 0.39 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |